Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)

LOS ANGELES, March 18 /PRNewswire/ -- Vista Partners announced today that
it has initiated coverage on leading Australian biotechnology company Arana
Therapeutics, (ASX: AAH; AIM: AAHx). "Cash on hand and royalty revenue alone
are equal to roughly US$0.94 in share value. Add to that our US$0.43
probability weighted, DCF value for ART621 and you have a premium of nearly
70% to the current market price. This comes without assigning any value to
their current pre-clinical pipeline which we feel has great potential," said
Ross Silver, Director of Research for Vista Partners. For more information and
to download the free report, please visit the Vista Partners website at
www.vistap.com.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and
individual investors, with a focus on publicly traded small capitalization
companies. With offices in Los Angeles and San Francisco, Vista Partners is
one of the fastest growing independently owned equity research firms. Vista
Partners professional staff has backgrounds in finance, corporate
communications and investment banking. More information is available at
www.vistap.com.
About Arana Therapeutics:
Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international
biopharmaceutical company formed through the merger of Peptech and EvoGenix in
August 2007. The company uses superior technology to develop next generation
drugs that will improve the lives of patients with inflammatory diseases and
cancer. Arana Therapeutics' innovative engineering technologies provide the
basis for clinical development in the antibody space, a market which draws on
high demand. Arana Therapeutics has the financial stability and management
expertise to accelerate its clinical programs, and is on track to have at
least 3 clinical stage assets within three years. Arana is listed on the
Australian Securities Exchange (ASX) and the London Stock Exchange (AIM). The
pipeline consists of four lead drug programs: ART621 to treat severe
rheumatoid arthritis, psoriasis and other inflammatory diseases; ART010 to
treat osteoporosis and bone cancer; ART104 to treat solid tumours in
colorectal cancer; and ART150 for lung cancer and melanoma. Additionally, the
company has earlier stage products in development for the treatment of a range
of conditions including age related macular degeneration, psoriasis,
colorectal cancer, and leukemia. Arana has recurring revenues from commercial
and development partnerships with six international companies including GSK,
CSL, Centocor (J&J) and Abbott Laboratories.
Contact:
Vista Partners LLC
Ross Silver
(310) 744-5268
info@vistap.com
www.vistap.com

SOURCE Vista Partners

Ross Silver of Vista Partners LLC, +1-310-744-5268, info@vistap.com